Skip to content

Clinical study of the efficacy and safety of ciprofol on gastroscopy in patients with obesity based on different weight-based scalars

Clinical study of the efficacy and safety of ciprofol on gastroscopy in patients with obesity based on different weight-based scalars

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2300073539
Enrollment
Unknown
Registered
2023-07-13
Start date
2023-09-01
Completion date
Unknown
Last updated
2025-02-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Diseases that require a gastroscopy

Interventions

Total Weight Group (Group T):based on total body weight for administration of ciprofol
Ideal Weight Group (Group I):based on ideal body weight for administration of ciprofol
Lean Weight Group (Group L):based on lean body weight for administration of ciprofol

Sponsors

Shunde Hospital of Southern Medical University (The First People's Hospital of Shunde)
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 65 Years

Inclusion criteria

Inclusion criteria: 1. Aged 18–65 years; 2.Patients undergoing diagnostic gastroscopy and simple treatment under gastroscopy for various reasons; 3.American Society of Anaesthesiologists (ASA) grade of I–II; 4.body mass index (BMI) between 28 and 39.9 kg/m2; 5.Both the patients and their families were fully aware of the study objective and provided signed informed consent.

Exclusion criteria

Exclusion criteria: 1.Endoscopic diagnostic and therapeutic techniques with longer operating times and more complex procedures, including endoscopic retrograde cholangiography, endoscopic ultrasound, endoscopic mucosal resection, endoscopic submucosal dissection, peroral endoscopic myotomy, and small enteroscopy. 2.Patients undergoing emergency procedures; 3.History of a negative response to anaesthesia, such as an allergic reaction to the anaesthetic or familial predisposition to malignant hyperthermia; 4.Bradycardia or other severe cardiovascular conditions; 5.Severe injuries or diseases affecting critical organs, such as the lungs, brain, liver, or kidneys; 6.Severe mental disorders; 7.History of substance addiction or drug abuse.

Design outcomes

Primary

MeasureTime frame
General anaesthesia success rate achieved by the initial dose;Success rate of induction of general anaesthesia;

Secondary

MeasureTime frame
Remedial sedation;Frequency of remedial sedation;Total dose of ciprofol;Gastroscopy time;Recovery time;Time to restore directional force;PACU residence time;vital signs;

Countries

China

Contacts

Public ContactYanjing Zhang

Shunde Hospital of Southern Medical University (The First People's Hospital of Shunde)

1148644826@qq.com+86 181 2480 9796

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026